Krishna Institute of Medical Sciences: Should You Buy, Hold, or Sell Right Now?

Krishna Institute of Medical Sciences share price has pulled back from its 52-week high of Rs 858, and KIMS share price now trades near Rs 754 on the NSE, well above its 52-week low of Rs 575.80. With revenue growing strongly but profit falling sharply in Q1 FY27, this article looks carefully at whether KIMS is a stock to buy given its expansion story, a hold, or a sell given the very rich valuation against declining profit.

This KIMS stock analysis walks through the Q1 FY27 numbers, the likely drivers behind the profit decline, valuation against the hospital sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings. Given the scale of the profit decline relative to the stock's valuation, this article aims to present the numbers with particular care.

Click Here – Get Free Investment Predictions

About Krishna Institute of Medical Sciences

This background is essential context for KIMS share price discussions. Keep this backdrop in mind when reading the rest of this KIMS share price review. Before deciding on KIMS share price, it helps to understand the underlying business. Krishna Institute of Medical Sciences Ltd. (KIMS) operates a chain of multi-speciality hospitals across South India, offering tertiary and quaternary healthcare services. The company has been aggressively expanding its hospital network, adding new beds and facilities across multiple cities to capture growing demand for quality healthcare services.

Like most hospital chains undertaking rapid capacity expansion, KIMS typically incurs significant upfront costs, including staffing, equipment and facility ramp-up expenses, for new hospitals before they reach mature occupancy and profitability, which can weigh meaningfully on consolidated margins during periods of aggressive network growth.

Krishna Institute of Medical Sciences Share Price Today: Key Levels

This snapshot is the starting point for any KIMS share price discussion. The table below summarises where KIMS share price stands right now against its recent trading range and market value.

Metric	Value
KIMS CMP (NSE)	Rs 753.65
KIMS CMP (BSE)	Rs 753.40
52-Week High	Rs 858.00
52-Week Low	Rs 575.80
Market Capitalisation	Approximately Rs 31,643 crore
NSE Volume (latest session)	284 shares

KIMS share price is trading in the middle of its 52-week range, even as the company's most recent quarter showed a sharp divergence between strong revenue growth and a steep profit decline that investors should examine closely.

Check the Univest Screener for Live Stock Data

Krishna Institute of Medical Sciences Financial Performance

These figures anchor the rest of this KIMS share price review. Track this line item closely if you are following KIMS share price closely. The KIMS share price trend is closely tied to how these numbers evolve each quarter. KIMS reported Q1 FY27 (June 2026 quarter) revenue of Rs 1,195.9 crore, up 36.1 percent year on year from Rs 878.7 crore, reflecting the company's aggressive hospital network expansion. However, net profit fell sharply, down 56 percent year on year, to Rs 37.4 crore from Rs 85 crore, continuing a declining quarterly profit trend that has run from Rs 85 crore in June 2025 down through Rs 72 crore, Rs 51.9 crore and Rs 33.1 crore in successive quarters before this latest figure.

For the full year FY26, the company reported revenue of Rs 3,930.8 crore, up 28.2 percent year on year, with net profit of Rs 242 crore, down 41.7 percent from Rs 414.8 crore in FY25, confirming that the profitability decline has been a sustained, multi-quarter trend rather than a single quarter's anomaly, likely tied to the costs of the company's rapid hospital network expansion.

Period	Revenue	Net Profit	Comment
Q1 FY27 (Jun 2026)	Rs 1,195.9 crore	Rs 37.4 crore	+36.1% revenue, -56% profit YoY
FY26 (full year)	Rs 3,930.8 crore	Rs 242 crore	+28.2% revenue, -41.7% profit YoY

Valuation Check: Is Krishna Institute of Medical Sciences Share Price Expensive?

This context matters for anyone assessing KIMS share price today. It is one of the clearest signals available on KIMS share price today. Any view on KIMS share price should start from these valuation multiples. KIMS share price currently reflects a price to earnings ratio of about 162.7 times trailing earnings, a very significant premium to the hospital sector average of roughly 67.5 times. The price to book ratio stands near 8.4 times, with return on equity at a modest 10.74 percent, a figure that looks especially stretched relative to the very high PE multiple.

Debt to equity of 1.89 reflects the capital intensity of the ongoing hospital network expansion. Historically, hospital chains investing heavily in new capacity have seen consolidated margins depressed during the ramp-up phase, but a combination of a sustained, multi-quarter profit decline alongside a PE multiple this elevated represents a genuine valuation risk that investors should weigh very carefully rather than assume will resolve automatically as new hospitals mature.

Technical Signals: What the Chart Shows

Watching KIMS share price over consecutive sessions gives a clearer read than any single print. Price action here often foreshadows the next move in KIMS share price. KIMS share price is currently positioned about 12 percent below its 52-week high of Rs 858 and roughly 31 percent above its 52-week low of Rs 575.80, placing it in the middle of its annual trading range despite the sustained profit decline over recent quarters. A stock trading in the middle of its range while profit has fallen for four consecutive quarters suggests the market has been giving the company the benefit of the doubt on its expansion story, which makes forthcoming quarters particularly important to watch.

Trading volumes remain moderate, so investors should track KIMS share price alongside new hospital occupancy ramp-up data in the coming quarters, rather than assuming the current valuation is fully justified by the expansion narrative alone.

Download the Univest iOS App or Univest Android App to track KIMS' live price and technical levels.

Shareholding Pattern

This detail is a useful reference point for KIMS share price discussions. Shifts here can influence KIMS share price more than headline news on some sessions. Krishna Institute of Medical Sciences has an institutional and public shareholder base that has grown since its stock market listing. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Krishna Institute of Medical Sciences

• Strong revenue growth from expansion: Q1 FY27 revenue grew 36.1 percent year on year, reflecting the scale benefits of the company's aggressive hospital network expansion.
• Established South India hospital brand: KIMS has built a recognised multi-speciality hospital brand across several South Indian cities, supporting patient volume growth.
• Potential margin recovery as new hospitals mature: If new hospital facilities reach mature occupancy levels over time, consolidated margins could improve from currently depressed levels.
• Scale benefits of a growing network: A larger hospital network can support better procurement, staffing efficiency and brand recognition over the long term.

Risks and Factors to Watch

• Sustained, multi-quarter profit decline: Net profit has fallen for four consecutive quarters, from Rs 85 crore to Rs 37.4 crore, a persistent trend that goes well beyond a single quarter's ramp-up cost.
• Very rich valuation relative to declining profit: A PE of 162.7 times against a hospital sector average of 67.5 times, combined with falling profit, represents a significant valuation risk if the market's patience for the expansion story wanes.
• Elevated leverage funding expansion: A debt to equity ratio of 1.89 adds financial risk during a period when consolidated profitability is already under pressure.
• Execution risk on hospital network expansion: Successfully ramping up new hospital facilities to mature, profitable occupancy levels requires sustained clinical and operational execution, and delays could extend the current margin pressure.

Krishna Institute of Medical Sciences Share Price Target: What the Data Suggests

That is the honest starting point for anyone assessing KIMS share price. Until then, KIMS share price remains best tracked through live, verified data rather than a single fixed number. KIMS does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, particularly given the scale of the recent profit decline relative to the stock's very rich valuation. What the data shows is a company delivering strong revenue growth from network expansion, but with profit falling for four consecutive quarters.

Historically, hospital chains investing in new capacity have seen valuations compress if margin recovery takes longer than the market initially expects. Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser given the significant gap between the current valuation and the recent profit trend.

Krishna Institute of Medical Sciences: Should You Buy, Hold, or Sell Right Now?

There is no shortcut here: KIMS share price needs to be judged against your own plan. This is the core question behind KIMS share price right now. The KIMS buy or sell decision requires weighing a very rich valuation against a truly concerning, sustained profit decline.

The case for buying: Investors who believe strongly in KIMS' hospital expansion story and expect new facilities to mature into profitability over the coming years may see the current pullback as an entry point, though this requires accepting the current valuation despite four straight quarters of profit decline.

The case for holding: Existing shareholders who already track KIMS' expansion trajectory may prefer to stay invested while watching closely for signs that the profit decline is stabilising.

The case for trimming or waiting: Investors concerned about the combination of a very high PE multiple and four consecutive quarters of declining profit may reasonably prefer to wait for clear evidence that margins have bottomed before committing fresh capital.

Given the scale of the valuation and profit divergence here, this decision deserves particular care, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

In short, KIMS share price calls for weighing these points together rather than in isolation. Krishna Institute of Medical Sciences share price reflects a hospital chain delivering strong revenue growth from network expansion, even as net profit has declined for four consecutive quarters, leaving the stock trading at a very rich valuation relative to its sector. Whether that makes the stock a buy, a hold or a sell right now depends on how much weight you place on the expansion story versus the sustained, real decline in profitability. This article is for informational purposes and not a personalised investment recommendation.

Q1. Is KIMS a good stock to buy right now?

Ans. KIMS grew Q1 FY27 revenue 36.1 percent year on year from hospital network expansion, but net profit has fallen for four consecutive quarters, down 56 percent in the latest quarter, while the stock trades at a very rich 162.7 times earnings. This combination warrants particular caution rather than being read simply as a growth story.

Q2. Why has KIMS profit been declining?

Ans. KIMS net profit has fallen for four consecutive quarters, from Rs 85 crore in June 2025 to Rs 37.4 crore in Q1 FY27, likely reflecting costs associated with the company's aggressive hospital network expansion, including staffing, equipment and facility ramp-up expenses for new hospitals that have not yet reached mature occupancy.

Q3. What is the KIMS share price today?

Ans. Krishna Institute of Medical Sciences share price is trading around Rs 754 on the NSE. The stock's 52-week high is Rs 858 and its 52-week low is Rs 575.80.

Q4. What is the KIMS share price target?

Ans. KIMS does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the scale of the recent profit decline relative to its valuation. Investors can check live research on the Univest Screener and should consult a SEBI-registered adviser given the elevated risk involved.

Q5. What is KIMS' market capitalisation and PE ratio?

Ans. KIMS has a market capitalisation of approximately Rs 31,643 crore and trades at a price to earnings ratio of about 162.7 times, a very significant premium to the hospital sector average PE of roughly 67.5 times.

Q6. Is KIMS profitable?

Ans. Yes, KIMS remains profitable, but its net profit has declined sharply and consistently over the past four quarters, falling 56 percent year on year to Rs 37.4 crore in Q1 FY27, even as revenue has continued to grow strongly.